Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Thalidomide-O-amido-PEG3-C2-NH2 TFA, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand based on Thalidomide and a 2-unit PEG linker for use in PROTAC technology[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 82.00 |
Description | Thalidomide-O-amido-PEG3-C2-NH2 TFA, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand based on Thalidomide and a 2-unit PEG linker for use in PROTAC technology[1]. |
In vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. |
Synonyms | Thalidomide-NH-PEG2-C2-NH2 TFA |
Molecular Weight | 518.44 |
Formula | C21H25F3N4O8 |
CAS No. | 2097509-36-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Thalidomide-PEG2-C2-NH2 TFA 2097509-36-7 Others ThalidomidePEG2C2NH2 TFA Thalidomide-NH-PEG2-C2-NH2 TFA Thalidomide PEG2 C2 NH2 TFA Thalidomide-PEG-2-C2-NH2 TFA inhibitor inhibit